BIODESIX, INC. BDSX 深 滬
等待開盤 09-11 09:30:00 美东时间
0.5216
+0.057
+12.37%
華盛通- 最 高0.53
- 今 開0.47
- 成交量 293.51万股
- 最 低 0.4581
- 昨 收 0.4642
- 總市值 7667.52万
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 2.00%
- 52周最低 0.1718
- 委 比 14.04%
- 總股本 1.47亿
- 歷史最高 31.99
- 量 比 0.16
- 振 幅 15.49%
- 歷史最低 0.1718
- 每 手 1
- 風險率 0.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference
Biodesix, Inc. announces that Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets' Annual Best Ideas Growth (BIG9) Conference on September 11, 2025, in New York. Biodesix is a leading diagnostic solutions company focused on improving clinical care and outcomes for patients with lung disease through its diagnostic tests and development services.
09-05 10:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Biodesix shares are trading higher after a Form 4 filing showed a director purchased 3,488,372 shares at an average price of $0.43.
Biodesix shares are trading higher after a Form 4 filing showed a director purc...
09-04 04:50
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
Biodesix, a leader in personalized diagnostics, was designated as a Thermo Fisher Scientific Center of Excellence. This collaboration advanced the validation of Thermo Fisher’s Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer, earning FDA approval. Biodesix contributed validation studies and data generation for regulatory submission. The partnership aims to enhance molecular diagnostic and NGS testing capabilities ...
08-19 13:47
Biodesix shares are trading lower after the company reported mixed Q2 financial results.
Biodesix shares are trading lower after the company reported mixed Q2 financial...
08-08 05:01
Biodesix Sees FY2025 Sales $80.000M-$85.000M vs $82.013M Est
Biodesix (NASDAQ:BDSX) sees FY2025 sales of $80.000 million-$85.000 million vs $82.013 million analyst estimate.
08-08 04:29
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
Biodesix, Inc. announced that CEO Scott Hutton and CFO Robin Cowie will participate in a fireside chat and hold 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The fireside chat will take place at 4:30 PM ET and will be webcast live on the Company's website. Biodesix provides diagnostic solutions for lung disease patients and offers development services to biopharmaceutical and research ...
08-05 10:00
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
Biodesix, Inc. will release its second-quarter 2025 financial results on August 7, followed by a conference call and webcast at 4:30 p.m. ET. Listeners can register via the provided links, with a replay available later on the company’s investor website. Biodesix offers diagnostic tests and development services to improve patient outcomes and support biopharmaceutical research. Forward-looking statements in this release involve risks and uncertain...
07-24 10:00
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Biodesix and APAPP collaborate to launch educational programs for healthcare providers on innovative diagnostic biomarkers, such as Nodify Lung® and IQLung® blood tests, to improve early detection and personalized treatment for lung cancer patients. The partnership aims to empower providers, especially in rural and resource-limited settings, to enhance patient care and outcomes.
06-10 10:17
